However, it is unlikely because combined treatment with CAM and either docetaxel or paclitaxel, both of which are chemotherapeutic reagents for breast cancer and are metabolized by CYP3A4 as well as BZ, did not result in any enhanced cytotoxicity in MDA-MB-231 cells, compared with treatment with each reagent alone (data not shown). Here, CYP3A4 is linked to breast cancer.